Antiviral drugs are prescription medicine such as pills, liquid, or intravenous solution to treat HIV, hepatitis B and C viruses, influenza A and B viruses, and herpes viruses. Antiviral drugs are different from antibiotics, which fight against bacterial infections.
Furthermore, the global antiviral drugs market is driven by increasing prevalence of viral infection such as HIV/AIDS. For instance, according to the report of Joint United Nations Programme (UNAIDS) (2021), there were 37.9 million people suffering from HIV/AIDS and around 770,000 people died from this disease globally in 2020.
Market Dynamics
Key players are focusing on product approvals to strengthen their position in the global antiviral drugs market.
For instance, in April 2021, Zydus Cadila, a pharmaceutical company has received Drug Controller General of India (DCGI) approval for its antiviral drug Virafin for the treatment of moderate COVID-19 infection in adults.
Key features of the study:
- This report provides in-depth analysis of the global antiviral drugs market, provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2021–2028), considering 2020 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global antiviral drugs market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include GlaxoSmithKline plc, AbbVie Inc., Merck & Co., Inc., Dr. Reddy's Laboratories Ltd., F. Hoffmann-La Roche AG, Bristol-Myers Squibb Company, Johnson & Johnson Services, Inc., Cipla Inc., Aurobindo Pharma, and Gilead Sciences
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global antiviral drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global antiviral drugs market
Detailed Segmentation:
- Global Antiviral Drugs Market, By Drug Class:
- DNA Polymerase Inhibitors
- Reverse Transcriptase Inhibitors
- Protease Inhibitors
- Neuraminidase Inhibitors
- Others
- Global Antiviral Drugs Market, By Type:
- Global Antiviral Drugs Market, By Application:
- HIV
- Hepatitis
- Herpes
- Influenza
- Others
- Global Antiviral Drugs Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Antiviral Drugs Market, By Region:
- North America
- Latin America
- By Country
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- By Country
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- By Country
- GCC
- Israel
- Rest of Middle East
- Africa
- By Country/Region
- South Africa
- Central Africa
- North Africa
- Company Profiles
- GlaxoSmithKline plc *
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- AbbVie Inc.
- Merck & Co., Inc.
- Reddy's Laboratories Ltd.
- Hoffmann-La Roche AG
- Bristol-Myers Squibb Company
- Johnson & Johnson Services, Inc.
- Cipla Inc.
- Aurobindo Pharma
- Gilead Sciences
“*” marked represents similar segmentation in other categories in the respective section.
